Population pharmacokinetic analysis in children with different diseases treated with mycophenolate mofetil—Integrated analysis of clinical trials and real-world clinical data

An integrated population PK model of MPA was developed in children with the following conditions: post-solid organ transplantation, post-HSCTx, autoimmune disease, and nephrotic syndrome. Estimated parameters and parameter covariates were similar to those previously reported. This model is expected to provide useful information for using MPA in various diseases in the Japanese population.